QTRX

The past six months have seen several events impacting Quanterix Corp.'s stock price. In Q4 2025, Quanterix reported a revenue increase but organic revenue declined, and the company reaffirmed its goal to achieve cash flow breakeven in the second half of 2026. Quanterix submitted a 510(k) premarket notification to the FDA for its multi-analyte algorithmic blood test for Alzheimer's disease. In Q1 2026, the company reported a revenue increase, but organic revenue declined, and the operating loss widened. Quanterix completed an $85 million annualized cost reduction plan and announced a collaboration with Tempus AI. The stock has experienced significant declines, trading near its 52-week low, and analysts have adjusted price targets downwards.